PCVX Vaxcyte, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649094 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-74.8%
TTM EPS YoY-66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-42.7%
ROA-37.3%
ROIC (approx.)-39.1%
Asset turnover—
Leverage & solvency
Liabilities / assets16.7%
Debt / equity0.00x
Current ratio4.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $794.31M | $476.64M |
| SG&A expense | $129.37M | $92.90M |
| Operating income | -$923.67M | -$569.55M |
| Interest expense | — | $0 |
| Income tax | $0 | $0 |
| Net income | -$766.63M | -$463.93M |
| EBITDA | -$907.28M | -$562.54M |
| EPS (basic) | -5.63 | -3.80 |
| EPS (diluted) | -5.63 | -3.80 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 136.09M | 122.00M |
| Balance sheet | ||
| Cash & equivalents | $173.96M | $389.19M |
| Short-term investments | $1.39B | $1.36B |
| Current assets | $1.63B | $1.79B |
| PP&E, net | $257.37M | $198.04M |
| Total assets | $3.00B | $3.51B |
| Current liabilities | $205.75M | $140.18M |
| Total liabilities | $317.21M | $205.50M |
| Shareholders' equity | $2.69B | $3.31B |
| Shares outstanding | 131.06M | 124.89M |
| Cash flow statement | ||
| Operating cash flow | -$655.58M | -$452.63M |
| Capital expenditure | $13.71M | $22.43M |
| Free cash flow | -$669.29M | -$475.05M |
| Investing cash flow | $437.35M | -$2.01B |
| Financing cash flow | $2.01M | $2.45B |
| Depreciation & amortization | $16.40M | $7.00M |
| Stock-based compensation | $138.84M | $84.82M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.